NEW YORK, June 29 (GenomeWeb News) - Cepheid and Applera have amended a license agreement between the companies to allow Cepheid to sell two of its real-time thermal cyclers to detect, characterize, and monitor HIV and hepatitis C infections, the companies said today.
"Although further licenses may be required to introduce clinical tests for quantitative detection of HIV and Hepatitis C, this first step removes a significant impediment to the development of those tests," said John Bishop, Cepheid CEO, in a statement.
The amended license agreement affects both Cepheid's SmartCycler and its GeneXpert platforms.